Press release
Palatin Technologies' UC Treatment Shows Remarkable 78% Clinical Response Rate in Phase 2 Topline Data - Potential Game-Changer for Millions Suffering from Ulcerative Colitis (NYSE: PTN)
Palatin Technologies (NYSE American: PTN)* just unveiled remarkable topline results from its Phase 2 study of PL8177 for ulcerative colitis (UC), demonstrating what could be a disruptive new treatment approach for this debilitating inflammatory bowel condition.
The data seems impressive - an extraordinary 78% of patients treated with PL8177 achieved clinical response compared to just 33% for placebo, with statistical significance (p
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Palatin Technologies' UC Treatment Shows Remarkable 78% Clinical Response Rate in Phase 2 Topline Data - Potential Game-Changer for Millions Suffering from Ulcerative Colitis (NYSE: PTN) here
News-ID: 3947959 • Views: …
More Releases from ABNewswire
Menhow Successfully Showcases Advanced Rubber Components at PLASTPOL 2025
Kielce, Poland - Menhow is proud to announce the successful conclusion of its participation at PLASTPOL 2025, one of the most prominent exhibitions for plastics and rubber processing in Central and Eastern Europe. Held in Kielce, the four-day event brought together industry leaders, innovators, and decision-makers to explore the latest advancements in materials and manufacturing.
Menhow attracted considerable attention at the event with its dynamic booth presentation, welcoming a steady flow…
Universal Translation Services Announces Transparent Pricing for Certified Trans …
Universal Translation Services has published a standardized price list for certified translations: $20 USD per page for official documents, plus optional Digital Certification ($10/doc), Notarization ($20/doc), and Hard-copy mailing (from $20). The policy formalizes long-standing practices around pricing transparency and document integrity. The company does not charge expedited or rush fees; time-sensitive requests are prioritized at no additional cost. Requests are submitted via their form.
Miami, Florida - September 19, 2025…
mCRPC Market Trends Point to Steady Growth Ahead by 2034, DelveInsight Analysis …
The Key Metastatic Castrate-resistant Prostate Cancer Companies in the market include - Janssen Research & Development, Pfizer, AstellasPharma, Bristol-Myers Squibb, Promontory Therapeutics, Hinova, Arcus Biosciences, Inc., AB Science, Suzhou Kintor Pharma, Tracon Pharma, Bayer, AstraZeneca, Clarity Pharma, Novartis, Endocyte, EMD Serono, Medivation, Inc., POINT Biopharma, and others.
DelveInsight's "Metastatic Castrate-resistant Prostate Cancer Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Metastatic Castrate-resistant Prostate Cancer, historical and…
Softek Awnings Highlights Affordable, Custom Door Awnings for Atlanta Properties
Softek Awnings, Atlanta's trusted provider of custom outdoor shade solutions, is expanding its residential and commercial offerings with a focus on affordable, custom-built door awnings. Designed to protect entryways from rain, sun, and snow while enhancing curb appeal, Softek's door awnings combine style with long-lasting durability.
September 19, 2025 - Atlanta, GA - With 25+ years of experience, Softek Awnings has become a leading authority on door awnings in Atlanta [https://softekawnings.com/services/door-awnings/],…
More Releases for Palatin
Moderate Dry Eye Market Growth to Accelerate in Forecast Period (2023-2032), Del …
The Key Moderate Dry Eye Companies in the market include - Palatin Technologies, Novaliq, mc2 therapeutics, and others.
The Moderate Dry Eye market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Moderate Dry Eye pipeline products will significantly revolutionize the Moderate Dry Eye market dynamics.
DelveInsight's "Moderate Dry Eye Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding…
Mild Dry Eye Market Growth Projections 2023-2032: DelveInsight Analysis | Palati …
The Key Mild Dry Eye Companies in the market include - Palatin Technologies, Novaliq, mc2 therapeutics, and others.
The Mild Dry Eye market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Mild Dry Eye pipeline products will significantly revolutionize the Mild Dry Eye market dynamics.
DelveInsight's "Mild Dry Eye Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding…
Dry Eye Disease Market Growth Projections 2024-2034: DelveInsight Analysis | Pal …
The Key Dry Eye Disease Companies in the market include - Palatin Technologies, Novaliq, mc2 therapeutics, and others.
The Dry Eye Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Dry Eye Disease pipeline products will significantly revolutionize the Dry Eye Disease market dynamics.
DelveInsight's "Dry Eye Disease Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding…
Dry Eye Disease Market to Expand Significantly by 2034, States DelveInsight Repo …
The Dry Eye Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Dry Eye Disease pipeline products will significantly revolutionize the Dry Eye Disease market dynamics.
DelveInsight's "Dry Eye Disease Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Dry Eye Disease, historical and forecasted epidemiology as well as the Dry Eye…
Palatin Technologies' Obesity Drug Receives FDA Orphan Designation; Phase 2 Resu …
Palatin Technologies (NYSE: PTN)* and their latest developments: Palatin's Oral MC4R Agonist Gets FDA Orphan Drug Status; Phase 2 Results in Drug Targeting $44 Billion Obesity Market Expected Any Day According to the Company, alongside results from ulcerative colitis trial; Only Oral Option in Market Currently Dominated by Injections Uniquely Positioning Palatin
In an exciting development for the biopharma market, Palatin Technologies (NYSE: PTN)* announced that it has secured FDA orphan…
Dry Eye Disease Market to Show Incremental Growth, asserts DelveInsight | Promin …
DelveInsight's "Dry Eye Disease Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Dry Eye Disease, historical and forecasted epidemiology as well as the Dry Eye Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Dry Eye Disease market report provides current treatment practices, emerging drugs, Dry Eye Disease market share of the individual therapies, current and forecasted…
